Q-omics provides the consensus-scored TRAJ24 profile across patient tissues and cancer cell-line models. TRAJ24 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TRAJ24 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, TRAJ24 RNA expression shows 14,303 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, KIRC, and LSCC as cancer lineages where TRAJ24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ24 survival associations across molecular data types. TRAJ24 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ24 RNA expression–survival associations across cancer types. High TRAJ24 expression shows unfavorable associations in UCS, KIRP, LGG and COAD, but favorable associations in OV and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for TRAJ24 RNA expression.
This table summarizes TRAJ24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ24 shows higher tumor expression in KIRC and STAD. The KIRC box plot shows higher TRAJ24 RNA expression in tumor versus normal tissue (log2 FC = +0.238, t-test p < 0.001).
This table shows molecular features associated with TRAJ24 in patient tissues and cancer cell lines. In patient samples, TRAJ24 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
